Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LUCY NASDAQ:NDRA NASDAQ:PFSA NYSE:RBOT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCYInnovative Eyewear$0.95-5.5%$1.05$0.90▼$4.97$6.44M2.6691,646 shs68,611 shsNDRAENDRA Life Sciences$5.04-10.0%$5.04$2.96▼$11.96$7.11M-0.0416,574 shs33,373 shsPFSAProfusa$0.32-5.4%$0.59$0.31▼$180.00$1.60M0.35227,786 shs189,253 shsRBOTVicarious Surgical$0.71-12.1%$0.74$0.27▼$13.75$5.07M1.7575,449 shs38,652 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCYInnovative Eyewear-5.47%-6.86%-7.87%-13.64%-69.55%NDRAENDRA Life Sciences-10.00%-3.08%+1.45%+38.46%+40.78%PFSAProfusa-5.40%-11.89%-42.32%-67.58%+32,389,900.00%RBOTVicarious Surgical-12.07%-25.81%+51.53%-20.78%-90.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCYInnovative Eyewear$0.95-5.5%$1.05$0.90▼$4.97$6.44M2.6691,646 shs68,611 shsNDRAENDRA Life Sciences$5.04-10.0%$5.04$2.96▼$11.96$7.11M-0.0416,574 shs33,373 shsPFSAProfusa$0.32-5.4%$0.59$0.31▼$180.00$1.60M0.35227,786 shs189,253 shsRBOTVicarious Surgical$0.71-12.1%$0.74$0.27▼$13.75$5.07M1.7575,449 shs38,652 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCYInnovative Eyewear-5.47%-6.86%-7.87%-13.64%-69.55%NDRAENDRA Life Sciences-10.00%-3.08%+1.45%+38.46%+40.78%PFSAProfusa-5.40%-11.89%-42.32%-67.58%+32,389,900.00%RBOTVicarious Surgical-12.07%-25.81%+51.53%-20.78%-90.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUCYInnovative Eyewear 1.00SellN/AN/ANDRAENDRA Life Sciences 2.00Hold$25.00396.03% UpsidePFSAProfusa 1.00SellN/AN/ARBOTVicarious Surgical 1.67Reduce$7.00882.87% UpsideCurrent Analyst Ratings BreakdownLatest PFSA, RBOT, NDRA, and LUCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026NDRAENDRA Life Sciences Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.004/21/2026LUCYInnovative Eyewear Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026NDRAENDRA Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026PFSAProfusa Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUCYInnovative Eyewear$2.66M2.29N/AN/A$1.69 per share0.56NDRAENDRA Life SciencesN/AN/AN/AN/A$1.92 per shareN/APFSAProfusa$100K15.09N/AN/A($21.69) per share-0.01RBOTVicarious SurgicalN/AN/AN/AN/A$7.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUCYInnovative Eyewear-$7.59M-$1.69N/AN/AN/A-272.42%-83.37%-76.02%8/13/2026 (Estimated)NDRAENDRA Life Sciences-$7.03M-$8.15N/AN/AN/AN/A-433.64%-204.58%8/13/2026 (Estimated)PFSAProfusa-$35.82M-$169.72N/AN/AN/AN/AN/A-1,348.07%N/ARBOTVicarious Surgical-$63.22M-$6.69N/AN/AN/AN/A-184.13%-112.50%7/30/2026 (Estimated)Latest PFSA, RBOT, NDRA, and LUCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026NDRAENDRA Life Sciences-$1.23-$1.09+$0.14-$1.09N/AN/A5/15/2026Q1 2026PFSAProfusaN/A-$2.05N/A-$2.05N/AN/A5/14/2026Q1 2026LUCYInnovative Eyewear-$0.47-$0.37+$0.10-$0.37$0.70 million$0.77 million3/25/2026Q4 2025LUCYInnovative Eyewear-$0.43-$0.28+$0.15-$0.28$1.20 million$0.96 million3/9/2026Q4 2025RBOTVicarious Surgical-$1.37-$1.65-$0.28-$1.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLUCYInnovative EyewearN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/APFSAProfusaN/AN/AN/AN/AN/ARBOTVicarious SurgicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUCYInnovative EyewearN/A8.026.09NDRAENDRA Life SciencesN/A0.640.64PFSAProfusaN/A0.020.02RBOTVicarious SurgicalN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUCYInnovative Eyewear0.96%NDRAENDRA Life Sciences1.19%PFSAProfusa9.81%RBOTVicarious Surgical47.27%Insider OwnershipCompanyInsider OwnershipLUCYInnovative Eyewear1.66%NDRAENDRA Life Sciences10.00%PFSAProfusa0.76%RBOTVicarious Surgical9.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLUCYInnovative Eyewear96.40 million6.30 millionNot OptionableNDRAENDRA Life Sciences201.27 million1.14 millionNot OptionablePFSAProfusa24.66 million4.63 millionN/ARBOTVicarious Surgical2107.12 million5.89 millionNo DataPFSA, RBOT, NDRA, and LUCY HeadlinesRecent News About These CompaniesVicarious Surgical (NYSE:RBOT) Stock Price Down 3.3% - Here's WhyMay 27, 2026 | americanbankingnews.comVicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical SettingMay 13, 2026 | globenewswire.comVicarious Surgical Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comVicarious Surgical Shareholders Approve Reverse Stock Split AuthorizationApril 8, 2026 | tipranks.comVicarious Surgical, Inc. Class AApril 7, 2026 | edition.cnn.comVicarious Surgical completes testing milestone for surgical robotMarch 30, 2026 | massdevice.comVicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairMarch 30, 2026 | globenewswire.comVicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq ListingMarch 25, 2026 | globenewswire.com‘Why do we exist?’: Inside Stephen From’s business strategy to get Vicarious Surgical to the finish lineMarch 20, 2026 | massdevice.comVicarious Fights to Stay Afloat & Other Medtech NewsMarch 19, 2026 | mddionline.comMThis surgical robotics company sees opportunity in hernia repairMarch 19, 2026 | medicaldesignandoutsourcing.comMVicarious Surgical pursues Nasdaq listing, cuts cash burn to $19MMarch 16, 2026 | massdevice.comVicarious Surgical applies for Nasdaq listingMarch 16, 2026 | medtechdive.comMVicarious Fights to Right the ShipMarch 16, 2026 | mddionline.comMVicarious Surgical Announces Strategic Plan to Pursue Nasdaq ListingMarch 16, 2026 | uk.finance.yahoo.comVicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 9, 2026 | businesswire.comVicarious Surgical Implements Executive Salary Reductions, Maintains IncentivesMarch 6, 2026 | tipranks.comVicarious Surgical receives NYSE delisting noticeMarch 4, 2026 | medtechdive.comMVicarious Surgical Confronted with NYSE Delisting Amid Ongoing ChallengesMarch 4, 2026 | mddionline.comMVicarious Surgical Receives Delisting Notice From NYSEMarch 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Intuit's Great SaaS Reset: Fired By AIBy Jeffrey Neal Johnson | May 22, 2026PFSA, RBOT, NDRA, and LUCY Company DescriptionsInnovative Eyewear NASDAQ:LUCY$0.95 -0.06 (-5.47%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.95 +0.00 (+0.21%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.ENDRA Life Sciences NASDAQ:NDRA$5.04 -0.56 (-10.00%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$5.07 +0.03 (+0.60%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Profusa NASDAQ:PFSA$0.32 -0.02 (-5.40%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.34 +0.02 (+4.66%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.Vicarious Surgical NYSE:RBOT$0.71 -0.10 (-12.07%) As of 06/2/2026 03:54 PM EasternVicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
